Squarepoint Ops LLC purchased a new stake in Opus Genetics, Inc. (NASDAQ: IRD) during the undefined

Opus Genetics receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-B

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy T

Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the p

Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy

Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula

U.S. stocks fell Wednesday as energy rose and discretionary slumped; Signet and Opus surged, while S

Opus Genetics, Inc. (NASDAQ:IRD) stock is surging on Wednesday after the company reported positive t

Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase

U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signe

U.S. stocks fell Wednesday, led by a 350-point Dow drop. Signet surged on strong earnings; oil, gold

Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre

OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events o

OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events o

Opus Genetics, Inc. (NASDAQ: IRD - Get Free Report) has received a consensus recommendation of "Mode

Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during inves

Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during inves

ADAR1 Capital Management LLC acquired a new position in Opus Genetics, Inc. (NASDAQ: IRD) during the

RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a

RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers

Common StockPreferred StockDebt SecuritiesWarrantsUnitsand up to 34,449,749 Shares of Common Stock I

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.14 per share versus the Zacks Consens

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst con

Topline six-month efficacy data expected by end of 2027Phase 3 study follows FDA alignment on regist

Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on regis

Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock stre

Opus Genetics, Inc. (NASDAQ:IRD) (the "Company", "Opus Genetics" or "Opus"),

RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (t

Opus Genetics has received the meeting minutes from the Type B meeting confirming several key elemen

Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates

Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stag

RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (t

Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and rai

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for In

Rapidly Advancing Five IRD Programs​ with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK

Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform

https://www.sec.gov/Archives/edgar/data/1228627/000114036126024283/ny20075388x1_s3.htm

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Opus Genetics (NASDAQ:IRD) with a B

RESEARCH TRIANGLE PARK, N. C. , June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD)

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a

Leerink Partners analyst Lili Nsongo initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outp

Citizens analyst Jonathan Wolleben maintains Opus Genetics (NASDAQ:IRD) with a Market Outperform

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.75) per share which missed the analyst c

Oral PresentationRestoration of Cone-Mediated Vision After Gene Augmentation in Children with LCA5Th

Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stag

Citizens analyst Jonathan Wolleben initiates coverage on Opus Genetics (NASDAQ:IRD) with a Market

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades and downg